Chao Liang

Dr. Chao Liang is an Associate Professor in the Department of Biology at Southern University of Science and Technology (SUSTech), where he has been employed since 2020. His work focuses on mechanistic studies, translational medicine, and precision medicine in bone & joint diseases and tumors. Previously, he served as a Post-doctoral Research Fellow and Research Assistant Professor at Hong Kong Baptist University from 2016 to 2020.

Education:

• Ph.D. in Biology (2016), Hong Kong Baptist University
• M.Sc. in Medical Sciences (2013), Anhui Medical University & Academy of Military Medical Sciences
• B.Sc. in Medical Sciences (2010), Taishan Medical University

Research Interests:

Dr. Liang's research spans three core areas: the molecular mechanisms underlying bone and joint diseases and tumors, the development of translational medicine approaches for these conditions, and the advancement of precision medicine strategies. His work integrates cutting-edge technologies such as CRISPR/Cas9, PROTACs, and aptamer-based therapeutics to develop targeted treatments for rheumatoid arthritis, osteosarcoma, and other musculoskeletal disorders.

Scientific Awards:

• 2014 ASBMR Young Investigator Award
• 2020 Shenzhen Overseas Senior Talents
• 2019 National Outstanding Youth

Research Impact & Grants:

Dr. Liang has led numerous high-impact studies resulting in over 30 peer-reviewed publications in top-tier journals such as Nature Medicine, Nature Communications, and The Lancet Rheumatology. His work on aptamer-functionalized therapeutics and PROTAC-based protein degradation has garnered significant attention for its potential to revolutionize treatment strategies in rheumatology and oncology. While specific grant details are not provided, his extensive publication record and prestigious awards indicate substantial research funding and support.

Labs & Teams:

Dr. Liang leads a dynamic research team at SUSTech, housed in the Department of Biology, School of Life Sciences. His lab focuses on interdisciplinary approaches combining molecular biology, pharmacology, and bioengineering to tackle complex diseases. The team collaborates extensively with international partners, leveraging expertise in gene editing, drug delivery systems, and precision medicine to drive translational research from bench to bedside.